Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study
PREMYOM1000
1 other identifier
observational
1,000
1 country
1
Brief Summary
Myopia and high myopia are the leading causes of visual impairment and blindness worldwide. The total number of myopic people globally was estimated to be 2.6 billion in 2020, and it could reach 4.8 billion by 2050 unless preventive interventions are implemented. Strategies to slow the progression of myopia, such as contact lenses, orthokeratology, atropine, and increased time spent outdoors, have shown promising results, although evidence varies depending on the method. However, most research has been conducted in Asia, and there are few studies on ocular growth in myopic children in Europe. Meanwhile, the prevalence of myopia is also increasing significantly in Europe, particularly in France. Understanding the growth of the myopic eye in European children is crucial. Cohort studies of myopic children are scarce and do not always include high-quality imaging. A cohort of myopic children with prospective collection of the best retinal and corneal images, along with ophthalmological exams to detail and model the growth of the myopic eye, will provide valuable insights to enhance our understanding of ocular growth and its inter-individual variability.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2025
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 19, 2025
CompletedFirst Posted
Study publicly available on registry
March 26, 2025
CompletedStudy Start
First participant enrolled
April 30, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2033
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 30, 2033
December 4, 2025
December 1, 2025
8 years
March 19, 2025
December 3, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
axial length
Measurement of axial length by IOL Master
Year 5
Interventions
alls exams included in ophtalmologic follow-up every 6 months for 5 years
all exams included in ophtalmological follow-up including axial length mesurment every 6 moths
Eligibility Criteria
Patients aged 6 to 17 years at inclusion, diagnosed with myopia (refractive error of -0.5 D or less in spherical equivalent in at least one eye)
You may qualify if:
- Myopia in at least one eye, defined as a refractive error in spherical equivalent ≤ -0.50 diopters (autorefraction under cycloplegia)
- Affiliated or beneficiary of a social security system
- Explicit consent from a holder of parental authority
You may not qualify if:
- Presence of trauma in both eyes
- Presence of inflammatory conditions in both eyes
- History of intraocular surgery (cataract, filtering surgery, intra-vitreal surgery) in both eyes
- Patient benefiting from legal protection measures
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Fondation A. de Rothschild
Paris, 75019, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Thibaut Chapron, Dr
Hôpital Fondation Adolphe de Rothschild
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 19, 2025
First Posted
March 26, 2025
Study Start
April 30, 2025
Primary Completion (Estimated)
April 30, 2033
Study Completion (Estimated)
April 30, 2033
Last Updated
December 4, 2025
Record last verified: 2025-12